Source: tech_eu

Evonetix: Bringing semiconductor tech to DNA synthesis, Evonetix secures 20 million

Cambridge-based spin-out company Evonetix has raised £20 million in a Series B funding round that's aimed at helping the company scale up the commercialisation of its DNA synthesis chip technology.The...

Read full article »

Evonetix's Competitors | Evonetix's News | Evonetix's Financials

Followers on Owler

Est. Annual Revenue

$5.0-25M

Est. Employees

25-100

CEO

Colin McCracken

CEO Approval Rating

90/100

Evonetix is an England-based synthetic biology company that develops and commercializes DNA synthesis for healthcare, pharmaceuticals and data storage markets.